The age standardised rates by (ASRs) Nordpred and joinpoint regression
| Cancer type (ICD-10 code) | Model | Observed/fitted ASRs | Projected ASRs | ||||
| 2001–2005 | 2006–2010 | 2011–2015 | 2016–2020 | 2021–2025 | 2026–2030 | ||
| KS (C46), both male and female | Nordpred* | 29.6 | 25.1 | 16.4 | 12.3 | 10.6 | 10.4 |
| Joinpoint† | 28.4 | 29.0 | 19.9 | 12.3 | 7.6 | 4.7 | |
| KS (C46), male | Nordpred* | 34.1 | 32.3 | 21.4 | 16.4 | 14.5 | 14.5 |
| Joinpoint† | 32.1 | 34.6 | 26.2 | 15.7 | 9.4 | 5.6 | |
| KS (C46), female | Nordpred* | 25.8 | 18.6 | 11.6 | 8.8 | 7.8 | 7.6 |
| Joinpoint† | 24.2 | 23.6 | 14.1 | 8.5 | 5.1 | 3.1 | |
| NHL (C83), both male and female | Nordpred* | 7.6 | 8.2 | 5.4 | 4.0 | 3.4 | 3.2 |
| Joinpoint† | 5.1 | 8.9 | 6.3 | 4.5 | 3.2 | 2.3 | |
| NHL (C83), male | Nordpred* | 9.1 | 9.5 | 5.9 | 4.2 | 3.3 | 3.1 |
| Joinpoint† | 7.8 | 7.0 | 6.2 | 5.6 | 5.0 | 4.4 | |
| NHL (C83), female | Nordpred* | 6.3 | 6.9 | 5.1 | 4.0 | 3.8 | 3.7 |
| Joinpoint† | 7.0 | 9.9 | 6.9 | 4.0 | 2.4 | 1.4 | |
| Cervical (C53) | Nordpred* | 52.6 | 56.0 | 60.5 | 63.7 | 65.8 | 66.1 |
| Joinpoint† | 51.7 | 55.1 | 58.8 | 62.7 | 66.8 | 71.2 | |
| Breast (C50) | Nordpred* | 33.2 | 35.2 | 37.6 | 40.6 | 44.1 | 48.4 |
| Joinpoint† | 31.8 | 34.3 | 37.0 | 39.8 | 42.9 | 46.2 | |
| Prostate (C61) | Nordpred* | 41.6 | 52.2 | 54.2 | 52.8 | 55.5 | 60.5 |
| Joinpoint† | 42.8 | 47.5 | 52.8 | 58.7 | 65.2 | 72.5 | |
*Observed ASRs and projected ASRs from Nordpred regression model for each 5-year period.
†Joinpoint regression model was fitted using annual data from 2001 to 2015 and projected up to 2030. Only fitted and projected ASRs of the first year of each period (2001, 2006, 2011, 2016, 2021, 2026) were presented.
ICD, International Statistical Classification of Diseases; KS, Kaposi sarcoma; NHL, non-Hodgkin's lymphoma.